Know Cancer

or
forgot password

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance


Phase 2
N/A
N/A
Not Enrolling
Both
Breast Neoplasms, Neoplasm Metastasis

Thank you

Trial Information

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance


This pilot trial will determine whether retroviral-transduced peripheral blood progenitor
cells (PBPCs) can be selected and expanded in vivo after non-ablative chemotherapy in
patients with metastatic breast cancer. It will also examine the feasibility of
administering induction high-dose therapy with antimetabolites, followed with consolidation
using high-dose single alkylating agent therapy and finally intensification therapy with
sequential cycles of very high doses of the natural product breast cancer chemotherapeutic
agents (paclitaxel followed by doxorubicin).

Patients will receive induction therapy with antimetabolite agents (methotrexate, leucovorin
and 5-fluorouracil) for two to four cycles. Patients will then receive consolidation
therapy with two cycles of high-dose alkylating agents. First, patients will receive one
cycle of high-dose cyclophosphamide administered with growth factor support. PBPCs will be
harvested during the recovery phase of the cyclophosphamide cycle.

One-half of the cells to be reinfused will be transduced with a retroviral vector containing
the gene for the multidrug resistance protein (MDRI in vector G1MD) and the other half will
be transduced with a vector containing the neomycin resistance gene (NeoR in vector
G1Na.40). Both of these vectors have previously been approved by the Recombinant DNA
Advisory Committee for PBPC transduction in Medicine Branch protocols.

The next cycle will consist of high-dose single agent thiotepa. Hematopoietic stem cells
mobilized and collected during the previous cyclophosphamide cycle and transduced with the
retroviral vectors will be reinfused following treatment with thiotepa to augment recovery
of bone marrow function. After recovery, intensification with natural product chemotherapy
will be administered, consisting of four cycles of paclitaxel given as a 24-hour infusion
followed by four cycles of single agent doxorubicin. Peripheral blood mononuclear cells
will be monitored following each cycle of paclitaxel and doxorubicin for the presence of the
MDRI and NeoR transgenes. The ration of the levels of MDRI to NeoR transgenes in peripheral
blood will determine whether in vivo expansion of the PBPCs containing the selectable MDRI
marker has been achieved.

This protocol combines several highly active chemotherapeutic agents in an attempt to
improve upon response rates achieved with current combinations. Patients who do not wish to
participate in the gene therapy procedures will be offered identical chemotherapy in a
different protocol.

Inclusion Criteria


Patients with stage IV breast cancer are eligible provided they have not received
chemotherapy for metastatic disease. Patients with stage IV breast cancer who have
received prior adjuvant chemotherapy are eligible.

Patients who have received prior doxorubicin therapy will be eligible. Patients who have
received a lifetime doxorubicin dose greater than 550 mg/m(2) or who have an initial MUGA
ejection fraction of between 40% and less than 50% will receive vinblastine instead of
doxorubicin.

Age greater than or equal to 18.

ECOG performance status of 0-2.

Adequate cardiac function as defined by an LVEF greater than or equal to 40% on MUGA scan
or an echocardiogram which demonstrates normal LV function.

Adequate hematologic function with neutrophils greater than 1,200/mm(3) and platelets less
than 100,000/mm(3) unless due to metastatic bone marrow involvement.

Adequate renal and hepatic function with creatinine less than 2.0 mg/dl, bilirubin less
than 1.8 mg/dl, and hepatic transaminases less than 2 times the upper limit of normal
unless due to metastatic cancer.

A 12-24 hour creatinine clearance greater than 50 ml/min.

No prior chemotherapy or radiation therapy within 3 weeks before starting protocol therapy
and patients must have recovered from any toxicity from any prior therapy.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

960007

NCT ID:

NCT00001493

Start Date:

October 1995

Completion Date:

June 2000

Related Keywords:

  • Breast Neoplasms
  • Neoplasm Metastasis
  • Dose Intensity
  • Gene Therapy
  • Multidrug Resistance
  • Breast Neoplasms
  • Neoplasms
  • Neoplasm Metastasis

Name

Location

National Cancer Institute (NCI)Bethesda, Maryland  20892